GERN / Geron (GERN) Up on Imetelstat Data on Myelodysplastic Syndromes

Geron Corporation stock has nearly halved since July, leading to concerns about whether the price will go back up. Geron's telomerase inhibitor imetel more_horizontal

Sell-off in Geron Corp (NASDAQ: GERN) over the past three months has created a great buying opportunity, says Corinne Jenkins – a Goldman Sachs anal more_horizontal

Geron (NASDAQ: GERN ) stock is gaining on Tuesday following an upgrade for the biopharmaceutical company's shares. Goldman Sachs analyst Corinne Jenki more_horizontal

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. more_horizontal

Geron Corporation (GERN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GERN's 50 more_horizontal

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that five abs more_horizontal

Geron's imetelstat has shown promise to treat a rare blood disorder. The drug could have wide oncology applications. more_horizontal

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. more_horizontal